Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIMS Prediction of Golimumab Response in Ulcerative Colitis
NCT02186886Phase 4Unknown
- Sponsor
- Kliniken im Naturpark Altmühltal
- Start
- Jun 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in ulcerative colitis (UC), sponsored by Kliniken im Naturpark Altmühltal. Primary endpoint: Clinical response at 14 weeks. Status: unknown.
02
Drugs
golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02186886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186886.